Trials / Unknown
UnknownNCT04659499
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer
A Multicenter, Open-label, Single-arm, Phase II Clinical Trial of Nab-paclitaxel in Combination With Pyrotinib in Adjuvant Therapy for Lymph Node-negative and Small Tumor HER2-positive Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 261 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, single-arm, prospective, phase II study. conducted to evaluate the efficacy, safety and tolerability of nab-paclitaxel plus pyrotinib in patients with lymph node-negative and tumor size ≤3 cm, HER2 positive breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nab-paclitaxel in combination with pyrotinib | Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2022-06-01
- Completion
- 2025-06-01
- First posted
- 2020-12-09
- Last updated
- 2020-12-09
Source: ClinicalTrials.gov record NCT04659499. Inclusion in this directory is not an endorsement.